Index
Module 16 • Shock & Hemodynamics
Shock Syndromes II
69%
Data Tables
Shock Syndromes II
Mahmoud A. Ammar ~3 min read Module 16 of 20
37
/ 54

Shock Syndromes II

1

The authors reported that Black patients were 13% less likely to receive advanced PE therapy (thrombolysis,

catheter-directed treatment, surgical embolectomy, or extracorporeal membrane oxygenation) than

White patients (OR 0.87; 95% CI, 0.82–0.93; p<0.001), and Asian patients were 24% less likely than

others (OR 0.76; 95% CI, 0.70–0.83; p<0.001). Patients with Medicare insurance were 27% less likely

(OR 0.73; 95% CI, 0.70–0.76; p<0.001), Patients with Medicaid insurance were 32% less likely (OR 0.68;

95% CI, 0.64–0.71; p<0.001), and patients with β€œother-insurance” (including patients without insurance)

were 14% less likely (OR 0.86; 95% CI 0.81–0.91; p<0.001) to receive advanced therapy than patients

with private insurance.

2With respect to mortality, Hispanic patients had a 10% higher mortality rate than White patients (OR

1.10; 95% CI, 1.03–1.18; p=0.005), and Asian patients had a 50% higher mortality rate than others (OR

1.50; 95% CI, 1.35–1.65; p<0.001). Patients with the lowest income also had a 9% greater mortality rate

(OR 1.09; 95% CI, 1.04–1.14; p=0.001). Among patients with high-risk PE, Black, Hispanic, and Asian

patients had an 11%–50% higher mortality rate than White patients, independent of other factors (p<0.05

for all racial/ethnic groups).

Patient Cases

7

A 48-year-old woman (weight 75 kg) presents to the ED with shortness of breath. The patient’s hypoxemia

does not improve with supplemental oxygen, and her chest radiograph is not significant for any lung abnor-

malities. A contrasted chest CT scan reveals a PE in the subsegmental branch of the right pulmonary artery

and no RV dilation. The patient’s vital signs and significant laboratory values are as follows: heart rate 118

beats/minute, blood pressure 98/62 mm Hg, urinary output 1 mL/kg/hour, troponin T 0.06 ng/mL, brain

natriuretic peptide 60 pg/mL, lactate 0.9 mmol/L, and SCr 1.1 mg/dL. In addition to initiating a parenteral

anticoagulant, which is best for the patient?

A.Tenecteplase 40-mg bolus.
B.Alteplase 100-mg infusion over 2 hours.
C.Alteplase 50-mg bolus.
D.No thrombolytic therapy.
8

A 56-year-old man (weight 140 kg) with a history of smoking and chronic obstructive pulmonary disease

was admitted to the medical ICU with sudden-onset dyspnea, chest pain, and hypoxemia (Pao2 78%). A

chest CTA reveals a subsegmental PE. His blood pressure is 87/56 mm Hg, now requiring norepinephrine.

Which is the next best step to evaluate and/or treat his PE?

A.Administer tenecteplase 40-mg intravenous push, followed by a therapeutic heparin infusion.
B.Obtain an echocardiogram and cardiac enzymes to guide further risk stratification.
C.Administer catheter-directed alteplase 1 mg/hour for 12 hours by EKOS EndoWave system catheter.
D.Administer alteplase 100 mg infused over 2 hours, followed by a therapeutic heparin infusion.
Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 36 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube